We aim to develop innovative disease-modifying therapeutics to preserve and improve patients’ vision. The strength of our ophthalmology pipeline derives from our strong clinical development capability and close collaboration with industry and academic partners coupled with our deep scientific knowledge of diseases affecting the eye.
With a diverse portfolio of drugs and drug candidates at different stages of development, we are focused on bringing patients safe and effective, best-in-class therapeutics for a spectrum of ophthalmic diseases in both the front and the back of the eye. The ophthalmic disease states we are targeting all are underserved clinically, with significant unmet medical needs in Greater China and other Asian countries.
| Program | Lead Indication | AffaMed Territory | Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AM007DEXTENZA Detail |
Post surgical pain/infl, AC | Greater China, Korea, SEA |
  |
|||||||||
|
MINI WELL Detail |
Cataract | Greater China |
|
|||||||||
|
MINI WELL Proxa Detail |
Cataract | Greater China |
|
|||||||||
|
MINI WELL Toric Detail |
Cataract | Greater China |
|
|||||||||
|
Evolux Detail |
Cataract | Greater China |
|
|||||||||
|
MINI 4 Ready Detail |
Cataract | Greater China |
|
|||||||||
|
AM712ASKG712 Detail |
nAMD, DME | Global (excl. Asia & Japan) |
|
|||||||||
|
AM008OTX-TIC Detail |
Glaucoma | Greater China, Korea, SEA |
|
|||||||||
|
AM305AG-73305 Detail |
DME, nAMD, RVO | Greater China, South Korea & SEA |
|
|||||||||
|
AM011Luminate Detail |
Dry AMD | Greater China |
|
|||||||||
|
AM007DEXTENZA
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Post surgical pain/infl, AC
|
|||||||||
|
AffaMed Territory
Greater China, Korea, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
MINI WELL
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
MINI WELL Proxa
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
MINI WELL Toric
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
Evolux
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
MINI 4 Ready
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Cataract
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM712ASKG712
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
nAMD, DME
|
|||||||||
|
AffaMed Territory
Global (excl. Asia & Japan)
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM008OTX-TIC
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Glaucoma
|
|||||||||
|
AffaMed Territory
Greater China, Korea, SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM305AG-73305
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
DME, nAMD, RVO
|
|||||||||
|
AffaMed Territory
Greater China, South Korea & SEA
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
|
AM011Luminate
Read More |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Lead Indication
Dry AMD
|
|||||||||
|
AffaMed Territory
Greater China
|
|||||||||
| Pre-clinical/IND | Phase I | Phase II | Phase III | Approved | |||||
|
|
|||||||||
